Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
Purity: ≥98%
This is a DEA controlled substance schedule IV Suvorexant (also known as MK-4305) is a potent dual OX receptor antagonist with Ki of 0.55 nM and 0.35 nM for OX1 receptor and OX2 receptor, respectively. Suvorexant is a medication that Merck is developing to treat insomnia. Phase III trials are presently being conducted on it. Suvorexant functions by inhibiting wakefulness as opposed to promoting sleep. Suvorexant (MK-4305), a dual orexin receptor (OXR) antagonist (DORA), has demonstrated potential in the treatment of insomnia and sleep disorders.
ln Vitro |
|
||
---|---|---|---|
ln Vivo |
|
||
Enzyme Assay |
MK-4305 possesses a Ki value of 0.55 nM for OX1 receptor and 0.35 nM for OX2 receptor, making it a strong antagonist of both receptors.
|
||
Cell Assay |
Based on an MDS Pharma off-target screen of 170 enzymes, receptors, and ion channels, an in vitro investigation revealed that MK-4305 had a clean ancillary profile (>10000-fold selectivity for OX2R).
|
||
Animal Protocol |
|
||
References |
Molecular Formula |
C23H23CLN6O2
|
|
---|---|---|
Molecular Weight |
450.92
|
|
Exact Mass |
450.16
|
|
CAS # |
1030377-33-3
|
|
Related CAS # |
|
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
|
SMILES |
C[C@@H]1CCN(CCN1C(=O)C2=C(C=CC(=C2)C)N3N=CC=N3)C4=NC5=C(O4)C=CC(=C5)Cl
|
|
InChi Key |
JYTNQNCOQXFQPK-MRXNPFEDSA-N
|
|
InChi Code |
InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1
|
|
Chemical Name |
[(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl]-[5-methyl-2-(triazol-2-yl)phenyl]methanone
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.2177 mL | 11.0884 mL | 22.1769 mL | |
5 mM | 0.4435 mL | 2.2177 mL | 4.4354 mL | |
10 mM | 0.2218 mL | 1.1088 mL | 2.2177 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05145764 | Recruiting | Drug: Suvorexant Drug: Placebo |
Suvorexant Placebo Opioid Use Disorder |
Johns Hopkins University | March 30, 2022 | Phase 2 |
NCT05656534 | Recruiting | Drug: Suvorexant Drug: Placebo |
Alcohol Use Disorder | Ohio State University | November 29, 2022 | Early Phase 1 |
NCT05733286 | Recruiting | Drug: Suvorexant 20 mg Drug: Placebo |
Delirium in Old Age | Duke University | June 28, 2023 | Phase 2 |
NCT05593653 | Recruiting | Drug: Suvorexant Drug: Placebo |
Insomnia Diabetes |
Brigham and Women's Hospital |
January 6, 2023 | Phase 4 |
NCT04262193 | Recruiting | Drug: Suvorexant Drug: Suvorexant Placebo |
Sleep Opioid-use Disorder |
Wayne State University | February 1, 2021 | Phase 2 |